Key Points
- Insider Chandra Vargeese sold 3,228 shares of WAVE Life Sciences at an average price of $13.45 for $43,416.60, reducing her stake by 0.78% to 408,246 shares, and the sale was disclosed in an SEC filing.
- WAVE reported a quarterly EPS of -$0.32 (missing the -$0.30 consensus) and revenue of $7.61M versus $9.85M expected, with a negative net margin (−111.64%) and analysts forecasting -1.14 EPS for the current year.
- Analyst sentiment is broadly positive (average rating "Moderate Buy" with 14 Buys vs. 1 Sell) and a consensus target price of $32.69, while institutional investors own about 89.73% of the stock and the company has a market cap of ~$2.22B.
WAVE Life Sciences Ltd. (NASDAQ:WVE - Get Free Report) insider Chris Francis sold 1,883 shares of WAVE Life Sciences stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $13.45, for a total value of $25,326.35. Following the sale, the insider owned 61,867 shares in the company, valued at $832,111.15. This represents a 2.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Chris Francis also recently made the following trade(s):
- On Friday, January 2nd, Chris Francis sold 9,375 shares of WAVE Life Sciences stock. The stock was sold at an average price of $16.03, for a total value of $150,281.25.
- On Monday, December 8th, Chris Francis sold 441,031 shares of WAVE Life Sciences stock. The shares were sold at an average price of $14.57, for a total value of $6,425,821.67.
WAVE Life Sciences Price Performance
NASDAQ:WVE opened at $13.27 on Thursday. The firm's 50-day moving average price is $14.99 and its 200-day moving average price is $10.38. The company has a market capitalization of $2.22 billion, a PE ratio of -17.69 and a beta of -1.78. WAVE Life Sciences Ltd. has a 1-year low of $5.28 and a 1-year high of $21.73.
WAVE Life Sciences (NASDAQ:WVE - Get Free Report) last issued its quarterly earnings results on Monday, November 10th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.30) by ($0.02). WAVE Life Sciences had a negative net margin of 111.64% and a negative return on equity of 75.61%. The business had revenue of $7.61 million for the quarter, compared to analysts' expectations of $9.85 million. Equities analysts anticipate that WAVE Life Sciences Ltd. will post -1.14 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several equities analysts have recently weighed in on the company. Royal Bank Of Canada upgraded WAVE Life Sciences from a "sector perform" rating to an "outperform" rating and raised their price target for the company from $9.00 to $27.00 in a report on Monday, December 8th. HC Wainwright raised their price objective on shares of WAVE Life Sciences from $22.00 to $30.00 and gave the company a "buy" rating in a research note on Friday, December 19th. Leerink Partners reaffirmed an "outperform" rating on shares of WAVE Life Sciences in a report on Monday, December 8th. Cantor Fitzgerald increased their price target on shares of WAVE Life Sciences from $34.00 to $41.00 and gave the company an "overweight" rating in a report on Thursday, February 5th. Finally, UBS Group set a $32.00 price objective on shares of WAVE Life Sciences in a report on Tuesday, December 16th. Fourteen investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $32.69.
View Our Latest Research Report on WVE
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in the business. CWM LLC raised its holdings in WAVE Life Sciences by 6,729.0% in the 4th quarter. CWM LLC now owns 2,117 shares of the company's stock worth $36,000 after purchasing an additional 2,086 shares during the period. Bessemer Group Inc. raised its stake in WAVE Life Sciences by 1,156.3% during the 3rd quarter. Bessemer Group Inc. now owns 9,925 shares of the company's stock worth $72,000 after acquiring an additional 9,135 shares during the period. Russell Investments Group Ltd. raised its stake in WAVE Life Sciences by 1,441.6% during the 3rd quarter. Russell Investments Group Ltd. now owns 9,928 shares of the company's stock worth $73,000 after acquiring an additional 9,284 shares during the period. Ameritas Investment Partners Inc. lifted its holdings in WAVE Life Sciences by 18.7% during the second quarter. Ameritas Investment Partners Inc. now owns 11,444 shares of the company's stock valued at $74,000 after purchasing an additional 1,802 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its position in shares of WAVE Life Sciences by 44.8% in the second quarter. Tower Research Capital LLC TRC now owns 11,658 shares of the company's stock worth $76,000 after purchasing an additional 3,609 shares during the period. 89.73% of the stock is currently owned by institutional investors.
WAVE Life Sciences Company Profile
(
Get Free Report)
WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.
The company's pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington's disease, as well as early-stage cardiovascular and liver indications.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
